, Volume 39, Issue 5, pp 1835–1841 | Cite as

Inhibitory Effects of Astragaloside IV on Bleomycin-Induced Pulmonary Fibrosis in Rats Via Attenuation of Oxidative Stress and Inflammation



In this study, we investigated the effects of astragaloside IV (As-IV) on pulmonary fibrosis and its mechanisms of action. Sprague-Dawley rats were used in a model of pulmonary fibrosis induced by an intratracheal instillation of bleomycin (BLM). Rats were intraperitoneally injected with As-IV (10, 20, 50 mg/kg) daily for 28 days, while the rats in control and BLM groups were injected with a saline solution. The effects of As-IV treatment on pulmonary injury were evaluated with the lung wet/dry weight ratios, cell counts, and histopathologic. Oxidative stress was evaluated by detecting the levels of malondialdehyde (MDA), superoxide dismutase (SOD), total antioxidant capacity (T-AOC), and reactive oxygen species (ROS) in lung tissue. Inflammation was assessed by measuring the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in bronchoalveolar lavage fluid (BALF). The results indicated that As-IV treatment remarkably ameliorated BLM-induced pulmonary fibrosis and attenuated BLM-induced oxidative stress and inflammation. Our findings indicate that As-IV-mediated suppression of fibroproliferation may contribute to the anti-fibrotic effect against BLM-induced pulmonary fibrosis. Its mechanisms of action are associated with inhibiting oxidative stress and inflammatory response. In summary, our study suggests a therapeutic potential of As-IV in the treatment of pulmonary fibrosis.


astragaloside IV pulmonary fibrosis oxidative stress inflammation 


  1. 1.
    Crestani, B., S. Marchand-Adam, A. Fabre, M. Dehoux, and P. Soler. 2007. Mechanisms in pulmonary fibrosis. La Revue du Praticien 57: 2222–2226.PubMedGoogle Scholar
  2. 2.
    Fernandez, I.E., and O. Eickelberg. 2012. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380: 680–688.CrossRefPubMedGoogle Scholar
  3. 3.
    Wynn, T.A. 2008. Cellular and molecular mechanisms of fibrosis. Journal of Pathology 214: 199–210.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sisson, T.H., M. Mendez, K. Choi, et al. 2010. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 181: 254–263.CrossRefPubMedGoogle Scholar
  5. 5.
    Raghu, G., H.R. Collard, J.J. Egan, et al. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. American Journal of Respiratory and Critical Care Medicine 183: 788–824.CrossRefPubMedGoogle Scholar
  6. 6.
    Noble, P.W., C.E. Barkauskas, and D. Jiang. 2012. Pulmonary fibrosis: patterns and perpetrators. Journal of Clinical Investigation 122: 2756–2762.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zhao, L., X. Wang, Q. Chang, et al. 2010. Neferine, a bisbenzylisoquinline alkaloid attenuates bleomycin-induced pulmonary fibrosis. European Journal of Pharmacology 627: 304–312.CrossRefPubMedGoogle Scholar
  8. 8.
    Sener, G., N. Topaloglu, A.O. Sehirli, F. Ercan, and N. Gedik. 2007. Resveratrol alleviates bleomycin-induced lung injury in rats. Pulmonary Pharmacology & Therapeutics 20: 642–649.CrossRefGoogle Scholar
  9. 9.
    Kliment, C.R., and T.D. Oury. 2010. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radical Biology and Medicine 49: 707–717.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheresh, P., S.J. Kim, S. Tulasiram, and D.W. Kamp. 2013. Oxidative stress and pulmonary fibrosis. Biochimica et Biophysica Acta 1832: 1028–1040.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang, H., Y. Zhang, T. Xia, et al. 2013. Synergistic promotion of blood vessel regeneration by astragaloside IV and ferulic acid from electrospun fibrous mats. Molecular Pharmaceutics 10: 2394–2403.CrossRefPubMedGoogle Scholar
  12. 12.
    Qiu, L.H., X.J. Xie, and B.Q. Zhang. 2010. Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biological and Pharmaceutical Bulletin 33: 641–646.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu, W., X. Shao, L. Tian, et al. 2014. Astragaloside IV ameliorates renal fibrosis via the inhibition of mitogen-activated protein kinases and antiapoptosis in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics 350: 552–562.CrossRefPubMedGoogle Scholar
  14. 14.
    Gui, D., J. Huang, Y. Guo, et al. 2013. Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kB-mediated inflammatory genes expression. Cytokine 61: 970–977.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhang, W.J., P. Hufnagl, B.R. Binder, and J. Wojta. 2013. Anti-inflammatory activity of astragaloside IV is mediated by inhibition of NF-kB activation and adhesion molecule expression. Thrombosis and Haemostasis 90: 904–914.Google Scholar
  16. 16.
    Ko, J.K., F.Y. Lam, and A.P. Cheung. 2005. Amelioration of experimental colitis by Astragalus membranaceus through anti-oxidation and inhibition of adhesion molecule synthesis. World Journal of Gastroenterology 11: 5787–5794.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Chen, X.H., R.S. Sun, J.M. Hu, et al. 2009. Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice. Clinical and Experimental Pharmacology and Physiology 36: 146–153.CrossRefPubMedGoogle Scholar
  18. 18.
    Kinnula, V.L., C.L. Fattman, R.J. Tan, and T.D. Oury. 2005. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. American Journal of Respiratory and Critical Care Medicine 172: 417–422.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Walters, D.M., H.Y. Cho, and S.R. Kleeberger. 2008. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxidants and Redox Signaling 10: 321–332.CrossRefPubMedGoogle Scholar
  20. 20.
    Homer, R.J., J.A. Elias, C.G. Lee, and E. Herzog. 2011. Modern concepts on the role of inflammation in pulmonary fibrosis. Archives of Pathology and Laboratory Medicine 135: 780–788.PubMedGoogle Scholar
  21. 21.
    Bringardner, B.D., C.P. Baran, T.D. Eubank, and C.B. Marsh. 2008. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxidants and Redox Signaling 10: 287–301.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mouratis, M.A., and V. Aidinis. 2011. Modeling pulmonary fibrosis with bleomycin. Current Opinion in Pulmonary Medicine 17: 355–361.CrossRefPubMedGoogle Scholar
  23. 23.
    Wynn, T.A. 2011. Integrating mechanisms of pulmonary fibrosis. Journal of Experimental Medicine 208: 1339–1350.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Denis, M. 1992. Interleukin-6 in mouse hypersensitivity pneumonitis: changes in lung free cells following depletion of endogenous IL-6 or direct administration of IL-6. Journal of Leukocyte Biology 52: 197–201.PubMedGoogle Scholar
  25. 25.
    Caspary, W.J., D.A. Lanzo, and C. Niziak. 1982. Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron. Biochemistry 21: 334–338.CrossRefPubMedGoogle Scholar
  26. 26.
    Todd, N.W., I.G. Luzina, and S.P. Atamas. 2012. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis & Tissue Repair 5: 11.CrossRefGoogle Scholar
  27. 27.
    Del Rio, D., A.J. Stewart, and N. Pellegrini. 2005. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutrition, Metabolism, and Cardiovascular Diseases 15: 316–328.CrossRefPubMedGoogle Scholar
  28. 28.
    Dominici, M., K. Le Blanc, I. Mueller, et al. 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315–317.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of RespirationYantai Hospital of Traditional Chinese MedicineYantaiChina

Personalised recommendations